Geron Corp

NASDAQ: GERN
$3.73
+$0.05 (+1.4%)
Closing price April 18, 2024
Geron Corp is a biopharmaceutical company focused on developing treatments for blood cancers. Its main project, imetelstat, is a groundbreaking therapy aimed at stopping the spread of cancerous cells in certain blood disorders. This innovative drug is currently in advanced testing stages, showing promise for patients with specific types of myelodysplastic syndromes and myelofibrosis. Founded in 1990 and based in Foster City, California, Geron is at the forefront of research in telomerase inhibition, a novel approach in cancer treatment.
Source: Jon OggStocks are looking for direction after the first week of a sell-off on the heels of eight weeks of a rally. At the same time, investors are getting ready for year-end and positioning...
Source: courtesy of Groupon Inc.24/7 Wall St. is watching a few key moves in the market and economy on Friday that should all be points of consideration over the weekend. We are calling these the...
Source: ThinkstockSeeing Geron Corporation (NASDAQ: GERN) as one of the top gaining stories on the day brought back memories of when this company was the leader in stem cells. That was then, and...
This past week proved yet again that stocks do not just rise forever and ever. Investors are coming to grips with the notion that a bond purchase tapering from Ben Bernanke and the Federal Reserve...
Source: Jon OggStocks are back in the public interest, and investors are on the hunt for solid research ideas. 24/7 Wall St. reviews many analyst research calls from Wall Street and from boutique...
The stock market is mixed Tuesday, with the Dow Jones Industrial Average up 0.02%, the Nasdaq down 0.54% and the S&P 500 down 0.20%. Today’s winners include a pharmaceutical company...
Source: ThinkstockSome companies are in real trouble. Some are under severe industry pressure, and some are just faltering due to missteps and bad luck. With the economy remaining weak and with the...
These are the new members of  24/7 Wall St.’s “52-week Low Club.”Shares of Geron Corporation (NASDAQ: GERN) fell 55.86% to close at $1.28 on trading volume of 19.5 million shares. The...
The three major U.S. stock indexes opened lower this morning after a weekend of mixed news from Asia. China’s trade balance rose on falling imports and industrial production failed to meet...
Source: Photo by Spencer Platt/Getty ImagesStocks were mixed Monday, with the Dow Jones Industrial Average up 0.05%, the Nasdaq down 0.42% and the S&P 500 down 0.06%. Today’s winner was a company...
Geron Corp. (NASDAQ: GERN) has spent much of the past decade migrating from the key stem cell research player into a total dud. Now we have more news that may act as a further harbinger of a...
How many big movers can you see in one day in the biotech sector?  This is what investors should be asking.  If you didn’t know better you might think there was a collusion in the biotech space...
These are some of Wednesday’s top analyst upgrades, downgrades, and initiations seen from Wall Street research calls.Activision Blizzard Inc. (NASDAQ: ATVI) Reiterated Buy with $18 target at Argus....
When you have a credit rating downgrade of the U.S. followed by a 300+ point drop in the DJIA and another near-100 point drop in the NASDAQ, it is no shock at all that you are seeing some big...
24/7 Wall St. usually covers ten to fifteen analyst calls each morning that are having an impact on shares.  After going through these research calls at the end of the week (and during the week),...